Shots:

• The P-III study involves assessing of Evinacumab vs PBO in patients with homozygous familial hypercholesterolemia (HoFH) for 24wks.
• The P-III study results: reduction in LDL cholesterol (49% vs 47%); LDL cholesterol levels<100mg/dL (47% vs 23%); similar reduction in LDL cholesterol level in "negative/negative" patients; reduction in apolipoprotein B (ApoB)- non-HDL cholesterol and total cholesterol; AEs (66% vs 81%)
• Evinacumab is an investigational mAb targeting ANGPTL3- currently being evaluated in P-III study for HoFH and P-II studies for refractory hypercholesterolemia and severe hypertriglyceridemia and has received the US FDA’s BT designation for the treatment of hypercholesterolemia in patients with HoFH in 2017

Click here to­ read full press release/ article | Ref: Regeneron | Image: High Point University